Octinoxate Completed Phase 4 Trials for Melasma Treatment

IndicationsStatusPurposePhase
CompletedTreatment4
clinicaltrials.gov IdentifierTitleDrugs
NCT01695356
Ultraviolet and UV-Visible Light Photoprotection for the Treatment of Melasma